News + Resources
New NAM Report Finds Biopharmaceutical R&D Investment Crucial for Patients, the Economy
Thousands of life sciences companies from across the U.S. compete every day to bring the next generation of treatments and cures to market. Within this ecosystem, pharmaceutical manufacturers play a key role in developing new therapies and cures. By mobilizing their...
PULSE Statement on Finalized Joint Merger Guidelines from FTC, DOJ
Latest guidance could pose unintended consequences for life science ecosystem, pro-innovation M&A Washington, D.C. – In response to the latest merger guidelines released today by the Federal Trade Commission (FTC) and Department of Justice (DOJ), the Partnership...
Opinion: Proposed regulation would limit life-saving research in Ohio
Ohio has had incredible success in the life sciences in recent years. The first-ever novel gene therapy brain infusion for Parkinson’s disease was developed here, along with the first-ever gene therapy treatment for Duchenne’s muscular dystrophy. Add state-of-the-art...
In Case You Missed It: PULSE Webinar – Life Science M&A: Supporting the Next Generation of Biopharma Breakthroughs
In a recent PULSE webinar, top experts from across the U.S. life sciences ecosystem highlighted the unique importance of mergers and acquisitions (M&A) in bringing new biopharmaceutical breakthroughs to market. The panelists broke down the complex path to market for new treatments and cures, and how M&A is critical in allowing companies of all sizes to combine the necessary resources and expertise to advance these innovations.
The Legislative Pillars Supporting Innovation & Access in the Life Sciences Ecosystem
For nearly four decades, policymakers have prioritized bipartisan policies that incentivize investment in groundbreaking medical research – aiming to make new innovations accessible for millions of Americans.
Life Sciences Companies Leverage M&A, Specialized Expertise to Advance Biopharmaceutical Breakthroughs
Over the past several decades, the U.S. life sciences ecosystem has emerged as a global leader in innovation with more than 2,300 biopharmaceutical companies spanning every state. Pro-innovation mergers and acquisitions (M&A) have been a critical component of the...
Life Sciences Mergers and Acquisitions: A Vital Bridge Across the “Valley of Death”
Every day, life sciences innovators discover promising new therapies with the potential to transform our approach to treating life-altering or life-threatening diseases. But what lies between these initial discoveries and an FDA-approved treatment reaching patients is...
M&A Provides Vital Bridge for Life Science Innovation Amid Economic Headwinds, Market Demands
In one of the more challenging investment economies in decades, life science innovators are increasingly forced to face difficult economic headwinds and market demands in their pursuit of breakthrough treatments and cures.
In Case You Missed It: American Enterprise Institute Panelists Weigh in on FTC & DOJ’s Flawed Approach to Merger Enforcement
Following the public comment period on the FTC and DOJ's proposed merger guidelines, leading antitrust experts and economists expressed significant concerns about the dramatic shift in competition policy that the proposal represents. In a recent panel discussion...
U.S. Chamber of Commerce Survey: Regulators’ Proposed Approach to M&A Ignores Market Reality
A recent survey by the U.S Chamber of Commerce sheds new light on the flaws of the Federal Trade Commission (FTC) and Department of Justice’s proposed approach to review and enforcement of mergers and acquisitions (M&A).